Trial Profile
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Ipilimumab; Nivolumab
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms PDIGREE
- 23 Sep 2023 Planned End Date changed from 15 Sep 2023 to 15 Sep 2024.
- 23 Sep 2023 Planned primary completion date changed from 15 Sep 2023 to 15 Sep 2024.
- 01 Sep 2022 Planned End Date changed from 15 Sep 2022 to 15 Sep 2023.